Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia

Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30–40% of patients develop resistance to imatinib therapy. Although most resistance is caused by mutations in the BCR-ABL kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandyopadhyay, Shovik, Li, Junjie, Traer, Elie, Tyner, Jeffrey W., Zhou, Amy, Oh, Stephen T., Cheng, Ji-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515395/
https://www.ncbi.nlm.nih.gov/pubmed/28719608
http://dx.doi.org/10.1371/journal.pone.0179558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515395/
https://www.ncbi.nlm.nih.gov/pubmed/28719608
http://dx.doi.org/10.1371/journal.pone.0179558

Ejemplares similares